Evidence map›Paper›PMID 35236385›Full record

ArticleOrphanet journal of rare diseases2022

Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy.

Benoît Sanson, Caroline Stalens, Céline Guien, Luisa Villa, Catherine Eng, Sitraka Rabarimeriarijaona, Rafaëlle Bernard, Pascal Cintas, Guilhem Solé, Vincent Tiffreau and 9 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

Benoît SansonUniversité Côte d'Azur, Service Système Nerveux Périphérique & Muscle, Centre Hospitalier Universitaire de Nice, Nice, France. sanson.b@chu-nice.fr.ORCID 0000-0001-9714-0613
Caroline StalensMedical Affairs Department, AFM-Telethon, Evry, France.
Céline GuienAix Marseille Univ, INSERM, MMG, Bioinformatics and Genetics, Marseille, France.
Luisa VillaUniversité Côte d'Azur, Service Système Nerveux Périphérique & Muscle, Centre Hospitalier Universitaire de Nice, Nice, France.
Catherine EngMedical Affairs Department, AFM-Telethon, Evry, France.
Sitraka RabarimeriarijaonaAPHM, Hôpital Timone Enfants, Laboratoire de Génétique Moléculaire, Marseille, France.
Rafaëlle BernardAPHM, Hôpital Timone Enfants, Laboratoire de Génétique Moléculaire, Marseille, France.
Pascal CintasDepartment of Neurology, Toulouse University Hospital, Toulouse, France.
Guilhem SoléCentre de Référence des Maladies Neuromusculaires AOC, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.
Vincent TiffreauCentre de Référence des Maladies Neuromusculaires, Service de Médecine Physique et de Réadaptation, CHU de Lille, Lille, France.
Andoni Echaniz-LagunaDepartment of Neurology, APHP, Bicêtre University Hospital, Le Kremlin-Bicêtre, France.
Armelle MagotReferral Center for Neuromuscular Diseases Atlantique-Occitanie-Caraïbes, CHU Nantes, Nantes, France.
Raul Juntas MoralesDépartement de Neurologie, CHU de Montpellier, Montpellier, France.
François Constant BoyerNMD Reference Center, Reims Champagne-Ardenne University Hospital, EA3797, Reims, France.
Aleksandra Nadaj-PaklezaCentre de Référence des Maladies Neuromusculaires Atlantique-Occitanie-Caraïbes, FILNEMUS, Service de Neurologie, CHU d'Angers, Angers, France.
Agnès Jacquin-PiquesDepartment of Clinical Neurophysiology, CHU Dijon Bourgogne, Dijon, France.
Christophe Béroud *Aix Marseille Univ, INSERM, MMG, Bioinformatics and Genetics, Marseille, France.
Sabrina Sacconi *Université Côte d'Azur, Service Système Nerveux Périphérique & Muscle, Centre Hospitalier Universitaire de Nice, Nice, France.
French FSHD registry collaboration group
Inserm · FRAssistance Publique Hôpitaux de Marseille · FRAssociation Francaise contre les Myopathies · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Lille · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Reims · FRCentre National de la Recherche Scientifique · FRUniversité de Bourgogne · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFacioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent muscular dystrophies and currently has no treatment. Clinical and genetic heterogeneity are the main challenges to a full comprehension of the physiopathological mechanism. Improving our knowledge of FSHD is crucial to the development of future therapeutic trials and standards of care. National FSHD registries have been set up to this end. The French National Registry of FSHD combines a clinical evaluation form (CEF) and a self-report questionnaire (SRQ), filled out by a physician with expertise in neuromuscular dystrophies and by the patient, respectively. Aside from favoring recruitment, our strategy was devised to improve data quality. Indeed, the pairwise comparison of data from 281 patients for 39 items allowed for evaluating data accuracy. Kappa or intra-class coefficient (ICC) values were calculated to determine the correlation between answers provided in both the CEF and SRQ.

resultsPatients and physicians agreed on a majority of questions common to the SRQ and CEF (24 out of 39). Demographic, diagnosis- and care-related questions were generally answered consistently by the patient and the medical practitioner (kappa or ICC values of most items in these groups were greater than 0.8). Muscle function-related items, i.e. FSHD-specific signs, showed an overall medium to poor correlation between data provided in the two forms; the distribution of agreements in this section was markedly spread out and ranged from poor to good. In particular, there was very little agreement regarding the assessment of facial motricity and the presence of a winged scapula. However, patients and physicians agreed very well on the Vignos and Brooke scores. The report of symptoms not specific to FSHD showed general poor consistency.

conclusionsPatient and physician answers are largely concordant when addressing quantitative and objective items. Consequently, we updated collection forms by relying more on patient-reported data where appropriate. We hope the revised forms will reduce data collection time while ensuring the same quality standard. With the advent of artificial intelligence and automated decision-making, high-quality and reliable data are critical to develop top-performing algorithms to improve diagnosis, care, and evaluate the efficiency of upcoming treatments.

Indexed as

Muscular Dystrophy, FacioscapulohumeralPhysiciansArtificial IntelligenceHumansPatient Reported Outcome MeasuresRegistries

Identifiers

PMID35236385
PMCPMC8890461
OpenAlexW4214932259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.